Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside

Immune checkpoint inhibitors have transformed the landscape of oncological therapy, but at the price of a new array of immune related adverse events. Among these is β-cell failure, leading to checkpoint inhibitor-related autoimmune diabetes (CIADM) which entails substantial long-term morbidity. As o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Linda Wu, Venessa H. M. Tsang, Sarah C. Sasson, Alexander M. Menzies, Matteo S. Carlino, David A. Brown, Roderick Clifton-Bligh, Jenny E. Gunton
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	immune checkpoint inhibitor (ICI) diabetes mellitus type 1 diabetes immune related adverse events immunotherapy Diseases of the endocrine glands. Clinical endocrinology RC648-665
Acceso en línea:	https://doaj.org/article/1e56972a31f348d590db8b50daff2a0b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1e56972a31f348d590db8b50daff2a0b
record_format	dspace
spelling	oai:doaj.org-article:1e56972a31f348d590db8b50daff2a0b2021-11-05T16:29:51ZUnravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside1664-239210.3389/fendo.2021.764138https://doaj.org/article/1e56972a31f348d590db8b50daff2a0b2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fendo.2021.764138/fullhttps://doaj.org/toc/1664-2392Immune checkpoint inhibitors have transformed the landscape of oncological therapy, but at the price of a new array of immune related adverse events. Among these is β-cell failure, leading to checkpoint inhibitor-related autoimmune diabetes (CIADM) which entails substantial long-term morbidity. As our understanding of this novel disease grows, parallels and differences between CIADM and classic type 1 diabetes (T1D) may provide insights into the development of diabetes and identify novel potential therapeutic strategies. In this review, we outline the knowledge across the disciplines of endocrinology, oncology and immunology regarding the pathogenesis of CIADM and identify possible management strategies.Linda WuLinda WuLinda WuLinda WuVenessa H. M. TsangVenessa H. M. TsangSarah C. SassonSarah C. SassonSarah C. SassonAlexander M. MenziesAlexander M. MenziesAlexander M. MenziesMatteo S. CarlinoMatteo S. CarlinoMatteo S. CarlinoDavid A. BrownDavid A. BrownDavid A. BrownDavid A. BrownRoderick Clifton-BlighRoderick Clifton-BlighJenny E. GuntonJenny E. GuntonJenny E. GuntonFrontiers Media S.A.articleimmune checkpoint inhibitor (ICI)diabetes mellitustype 1 diabetesimmune related adverse eventsimmunotherapyDiseases of the endocrine glands. Clinical endocrinologyRC648-665ENFrontiers in Endocrinology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	immune checkpoint inhibitor (ICI) diabetes mellitus type 1 diabetes immune related adverse events immunotherapy Diseases of the endocrine glands. Clinical endocrinology RC648-665
spellingShingle	immune checkpoint inhibitor (ICI) diabetes mellitus type 1 diabetes immune related adverse events immunotherapy Diseases of the endocrine glands. Clinical endocrinology RC648-665 Linda Wu Linda Wu Linda Wu Linda Wu Venessa H. M. Tsang Venessa H. M. Tsang Sarah C. Sasson Sarah C. Sasson Sarah C. Sasson Alexander M. Menzies Alexander M. Menzies Alexander M. Menzies Matteo S. Carlino Matteo S. Carlino Matteo S. Carlino David A. Brown David A. Brown David A. Brown David A. Brown Roderick Clifton-Bligh Roderick Clifton-Bligh Jenny E. Gunton Jenny E. Gunton Jenny E. Gunton Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside
description	Immune checkpoint inhibitors have transformed the landscape of oncological therapy, but at the price of a new array of immune related adverse events. Among these is β-cell failure, leading to checkpoint inhibitor-related autoimmune diabetes (CIADM) which entails substantial long-term morbidity. As our understanding of this novel disease grows, parallels and differences between CIADM and classic type 1 diabetes (T1D) may provide insights into the development of diabetes and identify novel potential therapeutic strategies. In this review, we outline the knowledge across the disciplines of endocrinology, oncology and immunology regarding the pathogenesis of CIADM and identify possible management strategies.
format	article
author	Linda Wu Linda Wu Linda Wu Linda Wu Venessa H. M. Tsang Venessa H. M. Tsang Sarah C. Sasson Sarah C. Sasson Sarah C. Sasson Alexander M. Menzies Alexander M. Menzies Alexander M. Menzies Matteo S. Carlino Matteo S. Carlino Matteo S. Carlino David A. Brown David A. Brown David A. Brown David A. Brown Roderick Clifton-Bligh Roderick Clifton-Bligh Jenny E. Gunton Jenny E. Gunton Jenny E. Gunton
author_facet	Linda Wu Linda Wu Linda Wu Linda Wu Venessa H. M. Tsang Venessa H. M. Tsang Sarah C. Sasson Sarah C. Sasson Sarah C. Sasson Alexander M. Menzies Alexander M. Menzies Alexander M. Menzies Matteo S. Carlino Matteo S. Carlino Matteo S. Carlino David A. Brown David A. Brown David A. Brown David A. Brown Roderick Clifton-Bligh Roderick Clifton-Bligh Jenny E. Gunton Jenny E. Gunton Jenny E. Gunton
author_sort	Linda Wu
title	Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside
title_short	Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside
title_full	Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside
title_fullStr	Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside
title_full_unstemmed	Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside
title_sort	unravelling checkpoint inhibitor associated autoimmune diabetes: from bench to bedside
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/1e56972a31f348d590db8b50daff2a0b
work_keys_str_mv	AT lindawu unravellingcheckpointinhibitorassociatedautoimmunediabetesfrombenchtobedside AT lindawu unravellingcheckpointinhibitorassociatedautoimmunediabetesfrombenchtobedside AT lindawu unravellingcheckpointinhibitorassociatedautoimmunediabetesfrombenchtobedside AT lindawu unravellingcheckpointinhibitorassociatedautoimmunediabetesfrombenchtobedside AT venessahmtsang unravellingcheckpointinhibitorassociatedautoimmunediabetesfrombenchtobedside AT venessahmtsang unravellingcheckpointinhibitorassociatedautoimmunediabetesfrombenchtobedside AT sarahcsasson unravellingcheckpointinhibitorassociatedautoimmunediabetesfrombenchtobedside AT sarahcsasson unravellingcheckpointinhibitorassociatedautoimmunediabetesfrombenchtobedside AT sarahcsasson unravellingcheckpointinhibitorassociatedautoimmunediabetesfrombenchtobedside AT alexandermmenzies unravellingcheckpointinhibitorassociatedautoimmunediabetesfrombenchtobedside AT alexandermmenzies unravellingcheckpointinhibitorassociatedautoimmunediabetesfrombenchtobedside AT alexandermmenzies unravellingcheckpointinhibitorassociatedautoimmunediabetesfrombenchtobedside AT matteoscarlino unravellingcheckpointinhibitorassociatedautoimmunediabetesfrombenchtobedside AT matteoscarlino unravellingcheckpointinhibitorassociatedautoimmunediabetesfrombenchtobedside AT matteoscarlino unravellingcheckpointinhibitorassociatedautoimmunediabetesfrombenchtobedside AT davidabrown unravellingcheckpointinhibitorassociatedautoimmunediabetesfrombenchtobedside AT davidabrown unravellingcheckpointinhibitorassociatedautoimmunediabetesfrombenchtobedside AT davidabrown unravellingcheckpointinhibitorassociatedautoimmunediabetesfrombenchtobedside AT davidabrown unravellingcheckpointinhibitorassociatedautoimmunediabetesfrombenchtobedside AT roderickcliftonbligh unravellingcheckpointinhibitorassociatedautoimmunediabetesfrombenchtobedside AT roderickcliftonbligh unravellingcheckpointinhibitorassociatedautoimmunediabetesfrombenchtobedside AT jennyegunton unravellingcheckpointinhibitorassociatedautoimmunediabetesfrombenchtobedside AT jennyegunton unravellingcheckpointinhibitorassociatedautoimmunediabetesfrombenchtobedside AT jennyegunton unravellingcheckpointinhibitorassociatedautoimmunediabetesfrombenchtobedside
_version_	1718444147416760320

Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside

Ejemplares similares